Sensei Biotherapeutics Abandons Lead Candidate
Sensei Biotherapeutics, a Boston-based biotech, is abandoning its sole clinical-stage asset, solnerstotug, and cutting its workforce amidst a strategic review to maximize shareholder value.
The decision comes just weeks after the company released positive Phase I dose expansion data for the solid-tumor candidate, with plans to proceed to Phase II testing.
Phase I/II Study Results
In a Phase I/II study (NCT05864144), the six-month progression-free survival (PFS) reached 50% in anti-PD-L1 resistant patients treated with 15mg/kg solnerstotug.
About Solnerstotug
Solnerstotug is a monoclonal antibody targeting V-domain Ig suppressor of T-cell activation (VISTA), designed to be conditionally active in a low-pH tumor microenvironment.
The company is set to cut its workforce and consider next steps.
Author's summary: Sensei Biotherapeutics abandons lead candidate solnerstotug.